(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 37.25% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.63%.
Maxcyte's revenue in 2023 is $41,989,900.On average, 3 Wall Street analysts forecast MXCT's revenue for 2023 to be $5,881,261,438, with the lowest MXCT revenue forecast at $5,602,367,618, and the highest MXCT revenue forecast at $6,184,034,201.
In 2024, MXCT is forecast to generate $7,888,215,244 in revenue, with the lowest revenue forecast at $7,888,215,244 and the highest revenue forecast at $7,888,215,244.